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‘No Pink Ribbons’: How Women’s Lived Experiences With
Breast Atypia Inform Decisions Involving Risk-Reducing
Medications
Sarah L. Goff, MD,1,2 Reva Kleppel, MSW, MPH,1 Grace Makari-Judson, MD3
Division of General Medicine, University of Massachusetts Medical School-Baystate, Springfield, MA; 2Institute for
Healthcare Delivery and Population Science, University of Massachusetts Medical School-Baystate, Springfield, MA;
3
Division of Hematology-Oncology, University of Massachusetts Medical School-Baystate, Springfield, MA
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Purpose	Atypical hyperplasia (AH) is associated with a nearly 4-fold elevation of lifetime risk for breast cancer,
and lobular carcinoma in situ (LCIS) is associated with a 7- to 8-fold risk. Women with AH/LCIS make
numerous decisions in the course of treatment, including whether to take a risk-reducing medication,
an option relatively few women pursue. We explored women’s decision-making processes through
patient narratives in an effort to inform decision supports for AH/LCIS.
Methods	We conducted in-depth interviews with 20 English-speaking women with AH/LCIS and no subsequent
diagnosis of invasive breast cancer who had enrolled in the Rays of Hope Center for Breast Cancer
Research patient registry between April 5, 2012, and March 31, 2016. Interviews were audiotaped,
professionally transcribed, and qualitatively analyzed using thematic qualitative content analysis.
Results 	We identified three major narrative themes: 1) experiences with medical care; 2) decision-making; and 3)
making sense of AH/LCIS. Each major theme had several subthemes, many of which map onto existing
decisional theories and heuristics. Subthemes included the impact of life context on diagnosis meaning,
emotional responses, changes in self-concept and body image, and understanding of the risk-benefit of
risk-reducing medications.
Conclusions	This narrative analysis offers important insights into how lived experience may influence decisionmaking for women with AH/LCIS. Decision supports that focus not only on analytic decisional processes,
but also patients’ subjectivities and decisional heuristics, could prove useful for women and their health
care providers. (J Patient Cent Res Rev. 2018;5:158-166.)
Keywords	atypical hyperplasia; breast; breast cancer prevention; shared decision-making; patient narrative;
qualitative

“There’s really no place for someone like me. There’s no Pink [ribbon] to celebrate it
and there are no support groups … but it’s still scary and it’s still a big decision.”
					

A

– Woman with atypical hyperplasia of the breast

lthough atypical hyperplasia (AH) of the breast
is rare in the general population (2.4 out of
10,000 screening mammograms),1 it accounts
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for 10% of the benign breast disease found on biopsy.1
Despite AH’s benign designation, it is associated with
a 30% risk (relative risk: 4.0) of developing invasive
breast cancer in the 25 years following diagnosis.2-6
Patients diagnosed with lobular carcinoma in situ
(LCIS), a benign breast lesion managed similarly to AH,
carry a 30%–40% risk (relative risk: 8.0) of developing
invasive breast cancer over a lifetime.7 This is in contrast
to the increased risk for invasive breast cancer associated
Original Research

with alcohol use (relative risk: 1.32)8 and obesity in
postmenopausal women (relative risk: 1.26).9
Women with AH/LCIS and their health care
providers face several decision-making conundrums.
For example, there is equipoise regarding optimal
approaches to breast cancer screening for women with
AH/LCIS (eg, American Cancer Society guidelines
“do not recommend for or against” the use of magnetic
resonance imaging in this population).10 Decisions about
use of risk-reducing medications present challenges.
Hartmann et al, in a state-of-the-science review,11
noted that despite the effectiveness of risk-reducing
medications,12–14 many women elect not to take them.
An estimated 15.5% of women age 35–79 years are
eligible to use medication for primary prevention of
breast cancer,15 but less than 0.3% elect to do so.16
Theoretical explanations for this phenomenon
include low perceived personal risk for breast cancer,
concerns about medication side effects, psychological
differences between preventing the possibility of
developing breast cancer versus treating breast cancer,
physician discomfort with prescribing risk-reducing
medications, and women’s incomplete understanding
of both their risk for breast cancer and the risk-benefit
associated with risk-reducing medications. Although
choosing not to take a risk-reducing medication may
be the result of fully informed shared decision-making,
several of these explanatory theories speak to potential
failures to communicate risk effectively to women.
Shared decision-making has been increasingly viewed
as the most ethical approach to medical decisionmaking when there is equipoise in guidelines. When
a shared decision-making approach is used, health
care providers elicit patient preferences regarding
participation in decision-making and provide
understandable information about the options for
diagnosis, treatment, and/or management. The health
care provider also provides understandable information
about the risks and benefits of pursuing or not pursuing
a given option and elicits the patient’s values, utilities,
and life conditions that may factor into his or her
decision. Decision aids can help facilitate use of shared
decision-making principles.17
We asked women with AH/LCIS to share their
experiences, thoughts, and feelings related to their
Original Research

diagnosis of AH/LCIS, with the aim of identifying
and understanding factors that may contribute to how
they made decisions related to their diagnosis, both
in general and specific to the use of risk-reducing
medications. This type of narrative approach offers
the opportunity to explore a chronology of actions,
feelings, and embeddedness as well as how an
individual’s story nests within her life.18 Our ultimate
goal was to inform future development and testing of a
novel decision aid for women with AH/LCIS and their
health care providers.

METHODS

Population and Recruitment
We identified women who had enrolled in the Rays
of Hope Center for Breast Cancer Research patient
registry between April 5, 2012, and March 31, 2016;
were English speaking; were 30–80 years of age at
the time of diagnosis of atypical ductal hyperplasia,
atypical lobular hyperplasia, or LCIS; had consented
to be contacted through the registry for research
purposes; and who had not experienced a subsequent
diagnosis of breast cancer. All women who are at
least 18 years of age, have had an excisional breast
biopsy or breast surgery (reduction mammoplasty,
lumpectomy, or mastectomy), and have been seen
by a health care provider at Baystate Medical Center
(Springfield, MA) are invited to participate in the
registry. Registry participants reflect the demographics
of women who have had excisional breast biopsies
at Baystate. Written informed consent is obtained for
all registry participants by registry research staff, and
Baystate’s institutional review board approved the
study protocol.
Women with a diagnosis of ductal carcinoma in
situ or who had been diagnosed with breast cancer
subsequent to their AH/LCIS diagnosis were excluded
because we were most interested in the perspectives
of women facing decisions related to primary breast
cancer prevention alone.
We mailed three rounds of invitation letters (May
2015, September 2015, May 2016) to potentially
eligible women. The letter described the study and
asked potential participants to call the study’s research
assistant if they were interested in learning more
about the study or if they knew that they did not want
to participate. The letter also stated that if the research
www.aurora.org/jpcrr
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team did not hear back, a team member would call the
recipient to address any questions she might have and
to further assess her interest in participating.
We sent invitation letters to all women who met
eligibility criteria during the study time frame (n=43).
Four women called the study research assistant to
express interest in participating, and an additional 16
women were recruited during follow-up phone calls.
We stopped recruitment when theoretical saturation
was reached (no new concepts in four sequential
interviews).19
Interviews
The research team developed an interview guide
(Appendix 1, p. 166) and pilot tested it with female
hospital staff and medical residents to assess the
guide for clarity and content. Authors S.L.G. and R.K.
developed an a priori code book based on existing
literature regarding decision theory. A second-year
female internal medicine resident conducted the
first 5 interviews. The primary investigator, who has
extensive experience using qualitative methods,20-23
trained the resident in qualitative interview techniques.
A research staff member, who is trained as a public
health social worker and has expertise in conducting
in-depth interviews, conducted the subsequent 15
interviews. One participant’s husband accompanied
her to the interview; the rest of the interviews were
conducted with the participant alone.
Participants completed a brief demographic survey
at the end of their interview and were offered a $25
gift card in appreciation of their time. All interviews
were audiotaped and transcribed by a professional
transcriptionist.
Analysis
A deductive approach (ie, begin with a priori codes
based on prior research and theory) was used to
identify broad themes in the first 4 transcripts, then
the a priori code book was revised to reflect the new
themes identified. The research team (S.L.G., R.K.)
then identified granular concepts through independent
iterative open line-coding of the transcripts, labeling
new concepts as they were identified. Line-code
disagreements were resolved through discussion for
the first 15 transcripts, maintaining an “audit trail” of
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coding decisions. R.K. then coded the final 5 transcripts
and reviewed coding decisions with S.L.G. New broad
themes were identified as coding progressed, using
memos attached to lines of coded text to track these
emerging themes.
Codes continued to be organized into major themes
and subthemes during secondary (axial) coding, with
researchers returning to the transcripts as needed.24
Finally, identified themes were triangulated with
heuristic decisional theory, both to ground the analysis
in existing theory and to explore the potential for a
theory-based rationale for development of a novel
decision aid for women diagnosed with AH/LCIS and
their health care providers. This analytic approach
relied on qualitative interpretation of the data, with
rigor derived from use of two independent coders and
grounding the analysis in the transcript data and theory.

RESULTS

Of 20 study participants, 14 (70%) were between
45 and 64 years of age, 14 (70%) identified as
white, nearly half (n=9) had a bachelor’s degree or
higher, and the majority (n=16) were employed for
wages (Table 1). The median time from diagnosis to
interview for the 15 women with diagnosis dates was
1 year (range 0.5 to 4.0 years). Two women had elected
to have prophylactic mastectomies. Interviews lasted
from 15 to 45 minutes.
We identified three major themes, each with multiple
associated subthemes. Major themes included 1)
experiences with medical care, 2) decision-making, and
3) making sense of AH/LCIS. These themes and their
associated subthemes are described in detail hereafter,
along with illustrative quotes; many additional quotes
are reported in Table S1 (online only).
Experiences With Medical Care
Women described a range of experiences with health
care providers and the health care system in relation to
their AH/LCIS. Three dominant subthemes emerged:
a) overall experiences; b) mixed messages; and c)
advice to other women.
Overall Experiences With Care: Many women in the
study had positive experiences with their health care
providers and the health care system during the process
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Table 1. Participant Characteristics
Characteristic

n (%)

Age, mean (SD)
35–44 years

4 (20%)

45–54 years

10 (50%)

55–64 years

4 (20%)

>64 years

2 (10%)

Race
Hispanic

1 (5%)

Native American

1 (5%)

Black

4 (20%)

White

14 (60%)

Annual income
<$25,000

1 (5%)

$25,000–$49,999

5 (25%)

$50,000–$100,000

5 (25%)

>$100,000

3 (15%)

Prefer not to say

4 (20%)

Not provided

2 (10%)

Marital status
Single

1 (5%)

Separated

1 (5%)

Divorced

2 (10%)

Married

16 (80%)

Work status
Retired

2 (10%)

Employed for wages

16 (80%)

Not provided

2 (10%)

Education
High school/GED

3 (15%)

Some college

3 (15%)

Associate’s degree

3 (15%)

Bachelor’s degree

6 (30%)

Some graduate

1 (5%)

Graduate degree
Not provided

2 (10%)
2 (10%)

of being diagnosed and treated. Good communication
and trust typified the positive descriptions of care.
“I have to say the oncologist was wonderful. She
was … calming … very helpful and informative
… especially when I was first diagnosed. She did
diagrams and all that sort of thing.”

Original Research

Women also described negative experiences, including
unanticipated complications, feeling that their concerns
were minimized, and feeling that they had questions
that remained unanswered.
“I said I would rather have an [definitive] answer
[about the abnormality noted on the mammogram]
sooner, and he [physician] says –– ‘Well, everything
that I see says you’re fine. You don’t even need this
[breast biopsy]. I don’t know why you’re doing it.’
He was very dismissive, and he says –– ‘I guess if
you really want to we can go ahead and do it.’”
Mixed Messages: Some women felt that they received
conflicting guidance from health care providers
within and across both specialties and institutions. For
example, different doctors expressed differing opinions
about diagnostic and management approaches.
“How can someone tell me to take both boobs off,
and how can someone [else] tell me –– let’s just
watch it?”
Women recalled recommendations for mammography
and clinical breast examination ranged from every 6
months to yearly.
Advice to Other Women: Women made the following
recommendations for others facing a similar diagnosis:
ask a lot of questions, get a second opinion if you have
any doubt, be proactive, and do your own research.
Women also offered advice to physicians: offer written
information about both the disease and management
options, and provide explanations over time so they
can be heard, understood, and absorbed.
Decision-Making
Four subthemes related to decision-making were
identified: a) preferred role in decision-making; b)
decisional inputs; c) risk-reducing medication; and d)
understanding risk and benefit.
Preferred Role in Decision-Making: Women varied
in the extent to which they wished to actively participate
in decisions regarding biopsy, risk-reducing medication,
postbiopsy breast cancer screening and, for some women,
mastectomy. Some preferred to follow their health care
providers’ recommendations without much discussion.
“I’m one of those people who goes by what the
doctor says; if the doctor tells me to stand on my
head, I’m going to stand on my head.”

www.aurora.org/jpcrr
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Others desired a highly active role in decision-making,
and the remainder fell somewhere in between these
two extremes. Some women felt that the physician’s
approach to including them in decision-making was
consistent with their preferred role, while others would
have liked to be more involved, felt like they couldn’t
speak up, or didn’t feel heard when they did.
“I brought it up to the surgeon, and he looked at me
and he goes –– ‘X, come on. We've done this how
many times? Let's just keep going with this right
now.’ And he goes –– ‘I'll tell you when you need to
start thinking about something different.’”

risk-benefit perspective.
“It didn’t make sense to not take something that had
such a potential to reduce that risk.”

Decisional Inputs: Medical information, from both
inside and outside of the health care system, was a factor
in decision-making for most women. Information from
inside the health care system came from women’s health
care providers, their own knowledge as a health care
provider, and friends and family members who did not
provide direct care to the patient but were in a health field.
“I think, as a nurse, I had a clinical understanding
and approached it with, ‘Okay, I know why it needs
to be done.’”

Understanding Risk and Benefit: Understanding the
risks and benefits of treatment options is a critical
part of shared decision-making. Women generally
understood that there was an increased risk for breast
cancer associated with AH/LCIS, but few knew how
high the estimated risk is.
“I think they did [tell me about my risk for developing
breast cancer], but I truly don’t remember … okay,
it’s like zero percent or something, but that can
always change.”

Outside the health care system, women found
information online and elicited information from
friends, family members, and/or colleagues, some
of whom had personal experience with AH/LCIS or
breast cancer. Some women had a personal history of
multiple breast biopsies, other health issues, health
preferences, and/or a family history of breast cancer
that influenced their decision-making. We also found
that some women felt that they couldn’t really “hear”
the information given early in the process because of
their emotional state.
“I don’t think I heard anything he [doctor] was
saying, but his mouth was moving and he was …
giving me alternatives … just giving me options
and all I kept thinking about was, ‘Grrr-grrrgrrr… do I have cancer?’”

Making Sense of AH/LCIS
Also identified in interviews were ways in which
women attempted to make sense of their diagnosis.
This major theme had three associated subthemes: a)
emotional responses; b) impact on life; c) supportseeking; and d) living in a grey zone.

Risk-Reducing Medication: Women’s thoughts
on whether or not they should take risk-reducing
medication varied. Of the 20 women interviewed,
7 were taking a risk-reducing medication, 3 did not
discuss it during the interview, 8 had declined to take
it, and 2 had started then stopped due to side effects.
Some women felt that it made sense to them from a
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Others felt the potential risks outweighed the benefits
for them, and some women felt that taking a medication
with potential side effects was not warranted since they
did not have breast cancer. Others hesitated to take the
medication for other reasons.
“I did look it [diagnosis] up online but, I just feel
that it wasn’t cancer ... why take that drug, I don’t
need that drug in my system … that’s how I feel….”

Emotional Responses: Women expressed a range of
emotional responses to the diagnosis, emotions that
sometimes evolved over the course of their diagnostic
and postdiagnosis experiences. Fear, urgency to “do
something,” pragmatism, relief, feeling that a cancer
diagnosis was inevitable, concerns about body image
and sexuality, changes in self-concept, the power
that cancer-related terminology can have (weight of
words), and how women envisioned the cancer in their
bodies dominated these comments.
“But it absolutely 100 percent walloped me emotionally.
Just because I was so scared, so worried.”
“I just imagined that the mass they were talking
about was a little something lumpy. Looked like
maybe jelly or even like plastic or something …
little air balls and that made me imagine this is
why the cancer cells could hide because it’s so
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lumpy you can’t really see it around the regular
smooth … that kind of got crumbled up and that it
gives cancer a place to hide.”
Impact on Life: The AH/LCIS diagnosis had little
impact on some women’s lives, while for others it had
significant meaning. Some found positive takeaways
from the experience, such as “silver linings”:
“So, you know, shitty things can happen, but there’s
a silver lining because you see the good in so many
people. It was a really big wake-up call. So now
I’m more focused on eating better and taking care
of myself and getting to the gym. I just have a new
outlook in life.”
For other women, it had a persistent negative effect,
such as the discomfort of living with uncertainty.
“It’s like in the forefront on my mind always … I’m
still really worried. I worry about it a lot. It’s …
there, in the back of my mind … and I try very hard
to let it just be there and to live with it, but it’s not a
pleasant thing to have sitting back there.
Support-Seeking: Some women discussed the
importance of the emotional support they received or
the problem with the lack thereof, while others preferred
to handle their diagnosis themselves and did not seek
support. Family members specifically were a source
of emotional support for some, while others felt that
family added an emotional burden. Some participants
discussed the challenge of needing to provide support
for their children while also needing to take care of
themselves. Women also described the role of faith in
coping with the diagnosis.
“It’s funny because normally you would worry and
all that, and I just said, ‘You know what, it’s in
God’s hands. I can’t change it, you know?’”
Living in a Gray Zone: Some women talked about the
difficulty they had explaining their condition to others
because it was not a cancer diagnosis but is associated
with an increased risk for developing cancer.
“Dr. X and I were talking this spring; she thought
there’s really no place for somebody like me and
other women … that went through this ... because
there’s no Pink [ribbon] to celebrate it and there
are no support groups. But you know what? It’s
still scary and it’s still a big decision.
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Triangulation of Major Themes and Subthemes
With Decision Theory
Classical behavioral economics stipulates that people
make rational decisions based on the highest overall
benefit or utility (rational choice theory).25 However,
clinical decision-making consistently deviates from
rational choice theory, deviations explained by prospect
theory, which takes into account emotional aspects of
decision-making.26 The narratives women shared gave
evidence for both intuitive and analytic models of
decision-making, with emotions playing an important
role in intuitive decision-making. Many women in
the study demonstrated reliance on classic decisional
heuristics such as availability (eg, memories of recent
or vivid experiences), anchoring biases (eg, relying on
the first piece of information offered), loss aversion (eg,
tendency to avoid a bad outcome even if the “risk” of
that outcome is low, such as side effects of risk-reducing
medication), decisional regret (eg, a decision is assessed
based on which decision pathway will feel “less bad” if the
eventual outcome is undesirable), and affective heuristics
(eg, focus on values most pertinent to the individual).26
The close relationship between the factors that women
indicated influenced their decisions provides important
information for tailoring approaches to informed shared
decision-making regarding risk-reducing medications
for AH/LCIS.

DISCUSSION

In this qualitative study of women’s experiences with
AH or LCIS, women shared stories of both positive
and negative experiences with the health care system,
factors that potentially influenced their decisionmaking related to diagnosis, and how they made sense
of their experience. Each of the major themes we
identified has the potential to inform how a decision
aid might best serve women with the diagnosis of
AH/LCIS and their health care providers. Perhaps not
surprisingly, women’s perspectives varied, highlighting
the importance of the opportunity a decision aid based
on shared decision-making principles offers.
More than 30 years after Page and colleagues described
the pathological findings of AH,27 questions about
individual risk and disease management remain. The
impact of age at diagnosis and family history on the
risk estimate is debated.11 Recommendations regarding
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the need for excisional biopsy, optimal imaging, and
identification of women most likely to benefit from
risk-reducing medication continue to evolve.11

that women who felt that all their questions had been
answered by their clinician were more likely to take a
risk-reducing medication.34

Ensuring that women fully understand the concept
of breast cancer risk over time is of paramount
importance. For AH, the cumulative incidence of breast
cancer may be estimated to range from 18% to 40%
based on stratification by multiple foci of atypia.4 Once
there is an understanding of risk, then a discussion
can begin regarding the reduction in risk conferred
by medication and how this measures against the
probability of medication-associated adverse effects.
The experiences and perspectives of the women in
the current study reinforce the importance of many of
these recommendations.

The framework for decision-making in breast cancer
prevention formulated by Ozanne et al relies largely on
epidemiologic data,35 which is important, but this study
suggests that such a framework might benefit from
explicitly including exploration of theory-informed
intuitive elements of decision-making, such as values
and life context, along with analytic elements such as
numerical risks and benefits of decisions.

Shared decision-making generally has three
components: 1) introducing decisions to be made;
2) describing options, often integrating use of a
decision support aid; and 3) helping patients explore
their preferences based on their values and life
context.28 There appeared to be some variation in the
recommendations made to women participating in
this study both within and across disciplines. We also
found that while some women clearly understood that
their risk for developing invasive breast cancer was
substantially elevated, others seemed to have only a
vague sense that their risk was higher than average.
Many were not clear on the role of risk-reducing
medication for breast cancer prevention. These
findings suggest that a decision aid might prove useful
for women facing a diagnosis of AH/LCIS and may
help their health care providers elicit individualized
value-based and life-context preferences.
Prior studies have shown that insufficient understanding
about breast cancer risk contributed to women’s
decision to decline a risk-reducing medication.29-31
Holmberg et al conducted a narrative study of women’s
decisions regarding risk-reducing medication and
found that epidemiological data alone is not sufficient
for informed patient-centered decision-making about
chemoprevention32 and that whether AH/LCIS is
framed as a disease or as a risk factor for disease
makes a difference in how women perceive risk of
the medication. This was consistent with the findings
of Salant et al33 and Rondanina et al, who reported

164 JPCRR • Volume 5, Issue 2 • Spring 2018

Limitations
Although the study was not designed to recruit a
representative sample, it is a strength that nearly 30%
of participants identified with a racial or ethnic minority
population. One limitation of the study is that because
the registry from which women were recruited is
a tissue registry, most study participants had had a
surgical excision (vs only a percutaneous core needle
biopsy). Women who have only had a stereotactic core
biopsy may have a different perspective of risk. Women
in the registry are from one geographic region, which
could mean that their experiences reflect dominant local
practice. However, a number of women reported receiving
conflicting advice about management from health care
providers, making it less likely that homogeneous local
practice would have influenced findings. The women
in the study had relatively high levels of educational
attainment; women with lower educational attainment
may have offered different perspectives.
We only included women’s perspectives and
recollections, and their health care providers may have
had differing perspectives. It is somewhat unusual
for women with AH/LCIS to have had a mastectomy,
which also may have influenced some of our findings.

CONCLUSIONS

The narratives women shared in this study provide
important insights into the current state of informed
shared decision-making for patients diagnosed with
atypical hyperplasia or lobular carcinoma in situ.
Our findings suggest that a decision support aid that
provides a framework for systematically incorporating
both analytic and patient-specific contextual decisional
inputs into decision-making, versus a primarily
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analytic-focused approach, could benefit women
and health care providers in helping women make
more fully informed decisions regarding use of riskreducing medication for breast atypia.

Patient-Friendly Recap
• Certain breast lesions, known as atypical
hyperplasia or lobular carcinoma in situ, are
benign in nature. However, women with these
lesions are at greater risk to develop harmful
breast cancer later in life.
• Woman diagnosed with benign breast atypia
may be offered risk-reducing medication, but
few choose to use it.
• The authors found that women base their
decision whether or not to use medication on
myriad factors beyond the statistical risk of
developing cancer.
• Health care providers can benefit from
discerning each patient’s level of understanding
and personal values when attempting to inform
clinical decisions.
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Appendix 1. Atypical Hyperplasia (AH/LCIS) of the Breast: Interview Guide
1. Please tell me/us a little bit about yourself. [Prompt: Anything important to know about you, maybe about family,
hobbies and interests, work if that applies?]
2. People have different and varying perspectives or understanding of AH/LCIS, so I’d like to ask you to share your
understanding about your diagnosis of (AH/LCIS). [Prompt: What is known about risks for developing it, how it relates
to breast cancer risk?]
3. Now could you tell me about what you remember about finding out about your diagnosis? [Prompt: Who told you? How did
you feel when you first found out? How do you feel about the diagnosis now? Who did you tell about the diagnosis?]
4. Now I’d like to ask you to take me through the steps you took after finding out about your diagnosis. [Prompt:
chemoprevention, screening and follow-up, second opinion, own research, decisions made, decision inputs,
follow-up plans, resources, social network, physicians, nurses, books, internet]
- What sources of information did you find most helpful, if any?
- Was there anything you wanted to know but couldn’t find information about?
- If another woman asked your advice on what to do after receiving the diagnosis, what might you tell her?
5. Can you tell me a little about how this diagnosis impacted you initially, if at all? How has that changed, if at all,
since you were diagnosed? [Prompt: Emotional aspects, family life, evolution of perceptions]
6. Knowing what you know now, can you tell me about anything you think you might have done differently?
[Prompts: Not undergone certain tests, procedures, not sought other opinions, obtained second opinions]
7. Is there anything else you think is important that you would like us to know?
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